Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNASDAQ:APTONASDAQ:MGTXNASDAQ:OTLK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.90-0.3%$5.92$7.96▼$24.15$14.63M0.6316,359 shs16,357 shsAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsMGTXMeiraGTx$5.36+5.1%$5.86$3.85▼$8.75$430.76M1.3362,829 shs340,916 shsOTLKOutlook Therapeutics$1.80+10.4%$1.47$0.87▼$9.25$54.72M0.39764,828 shs1.36 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-0.34%-2.68%-56.78%-70.41%-82.96%APTOAptose Biosciences0.00%0.00%0.00%-46.39%-95.00%MGTXMeiraGTx+5.10%+5.93%-22.32%-24.82%+7.20%OTLKOutlook Therapeutics+10.43%+9.76%+15.38%+20.00%-74.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AAPTOAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMGTXMeiraGTx4.4628 of 5 stars3.52.00.04.82.02.51.9OTLKOutlook Therapeutics1.8511 of 5 stars3.43.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideMGTXMeiraGTx 3.00Buy$24.00347.76% UpsideOTLKOutlook Therapeutics 2.80Moderate Buy$10.20466.67% UpsideCurrent Analyst Ratings BreakdownLatest APTO, ALVR, MGTX, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.003/28/2025APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $6.003/17/2025MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$11.00 ➝ $13.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AMGTXMeiraGTx$34.51M12.48N/AN/A$2.17 per share2.47OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)APTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AMGTXMeiraGTx-$84.03M-$2.32N/A14.110.37-633.05%-146.38%-53.05%8/11/2025 (Estimated)OTLKOutlook Therapeutics-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)Latest APTO, ALVR, MGTX, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million3/13/2025Q4 2024MGTXMeiraGTx-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AAPTOAptose BiosciencesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78APTOAptose BiosciencesN/A1.051.05MGTXMeiraGTx0.862.342.34OTLKOutlook TherapeuticsN/A0.320.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%APTOAptose Biosciences26.62%MGTXMeiraGTx67.48%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%APTOAptose Biosciences1.33%MGTXMeiraGTx7.50%OTLKOutlook Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataMGTXMeiraGTx30080.37 million71.59 millionOptionableOTLKOutlook Therapeutics2033.57 million30.48 millionOptionableAPTO, ALVR, MGTX, and OTLK HeadlinesRecent News About These CompaniesOutlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $10.20 Consensus Price Target from AnalystsMay 27 at 3:49 AM | americanbankingnews.comOutlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Moderate Buy" by AnalystsMay 24, 2025 | marketbeat.comOutlook Therapeutics announces public stock offeringMay 24, 2025 | investing.comOutlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and WarrantsMay 24, 2025 | nasdaq.comOutlook Therapeutics announces proposed public offering of common stock, warrantsMay 23, 2025 | msn.comOutlook Therapeutics drops 17%, prices $13M stock offeringMay 23, 2025 | msn.comOutlook Therapeutics® Announces Pricing of $13.0 Million Public OfferingMay 23, 2025 | globenewswire.comOutlook Therapeutics® Announces Proposed Public Offering of Common Stock and WarrantsMay 22, 2025 | globenewswire.comTang Capital Management LLC Has $345,000 Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK)May 21, 2025 | marketbeat.comOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deOutlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comOutlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comWhy Outlook Therapeutics, Inc.’s (OTLK) Stock Is Down 6.40%May 15, 2025 | aaii.comMicrosoft shares big update on new Outlook enable/disable optionMay 12, 2025 | windowsreport.comWindows New Outlook will soon get offline Calendar supportMay 9, 2025 | windowsreport.comWant to use both new and classic Outlook apps? Soon, says MicrosoftMay 7, 2025 | msn.comClassic Outlook Gets a Smoother Experience in Windows 11May 7, 2025 | channelnews.com.auClassic Outlook will soon be easier to use in Windows 11May 7, 2025 | digitaltrends.comFDA accepts biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMDApril 10, 2025 | ophthalmologytimes.comOutlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010April 8, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMDApril 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPTO, ALVR, MGTX, and OTLK Company DescriptionsAlloVir NASDAQ:ALVR$2.90 -0.01 (-0.34%) As of 05/28/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Aptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.MeiraGTx NASDAQ:MGTX$5.36 +0.26 (+5.10%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$5.68 +0.32 (+5.88%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Outlook Therapeutics NASDAQ:OTLK$1.80 +0.17 (+10.43%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.74 -0.06 (-3.28%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
